Released May 13, 2026, after the close
10-Q filed May 13, 2026, 43 days after period end · 0001193125-26-221591
Q1 2026 · 10-Q
Revenue$0.00$0.00 −100.0% vs Q1 2025−100.0% vs Q4 2025
Net Income-$7.20M-$7.20M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.13-$0.13 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$7,538,000N/M
Operating Cash Flow$15,864,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $0.00 | $12.00K | $140.00K | $223.00K |
| Net Income | -$7.20M | -$13.87M | -$12.67M | -$13.30M |
| EPS Diluted | -$0.13 | -$0.25 | -$0.24 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR